Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea

Launched by MEDICAL UNIVERSITY OF GRAZ · May 15, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how the gut microbiome—the community of bacteria and other microorganisms living in our intestines—affects diarrhea that can happen as a side effect of cancer treatments. Researchers want to understand if changes in the gut microbiome can predict or influence the likelihood of experiencing diarrhea during anti-cancer therapy. This study is particularly focused on patients who are starting systemic anti-cancer treatments and will follow them over time to gather important information.

To participate in this trial, you need to be at least 18 years old and starting a new anti-cancer treatment. However, if you have had diarrhea before, are currently taking antibiotics or probiotics, or are unable to give informed consent, you won't be eligible to join. If you do participate, you'll help researchers learn more about the relationship between gut health and cancer treatment side effects, which could lead to better management of these issues in the future. Your involvement could make a significant difference in how we understand and treat side effects from cancer therapies!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Start of a systemic anti-cancer therapy
• • Informed consent
• Exclusion Criteria:
• • • Pre-existing diarrhoea
• • Antibiotic therapy -4 to -1 week before inclusion
• • Probiotic treatment -4 to -1 week before inclusion
• • Inability to give informed consent